Status:

UNKNOWN

IMMUNERECOV CONTRIBUTES TO IMPROVEMENT OF RESPIRATORY AND IMMUNOLOGICAL RESPONSE IN POST-COVID-19 PATIENTS.

Lead Sponsor:

Federal University of São Paulo

Conditions:

Long Covid19

Dietary Supplements

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Background: COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and per...

Detailed Description

Background: COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and per...

Eligibility Criteria

Inclusion

  • The inclusion criteria encompassed post-COVID-19 patients with a confirmed COVID-19 diagnosis through a positive RT-PCR test, who also required hospitalization, meeting the criteria for moderate severity classification as defined by the World Health Organization (WHO). In summary, according to the WHO, moderate illness is characterized by individuals who exhibit signs of lower respiratory disease during clinical assessment or imaging and maintain an oxygen saturation level (SpO2) of ≥94% while breathing room air at sea level.

Exclusion

  • Exclusion criteria included individuals discharged from the hospital for more than 14 days and those who initiated physical activity or began taking any dietary supplements or vitamins.

Key Trial Info

Start Date :

December 10 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 15 2024

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT06166030

Start Date

December 10 2023

End Date

December 15 2024

Last Update

December 12 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Laboratory of Pulmonary and Exercise Immunology - Federal University of Sao Paulo

São José dos Campos, São Paulo, Brazil, 12231-280

2

Laboratory of Pulmonary and Exercise Immunology

São José dos Campos, São Paulo, Brazil, 12231280

IMMUNERECOV CONTRIBUTES TO IMPROVEMENT OF RESPIRATORY AND IMMUNOLOGICAL RESPONSE IN POST-COVID-19 PATIENTS. | DecenTrialz